Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vir Biotechnology, Inc.VIR · Entity 4522 | EVP, Chief Financial Officer | October 05, 2026 | October 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vir Biotechnology, Inc.
Report date October 05, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2026-10-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theravance Biopharma, Inc.
Report date September 23, 2026 · Filed September 25, 2026
Section 16 reporting ended · disclosed 2026-09-25. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-23 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-23 · Disposition to issuer · Disposed 204,966 · Balance 131,875 F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Row 2 · 2026-09-23 · Disposition to issuer · Disposed 108,436 · Balance 23,439 F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Row 3 · 2026-09-23 · Disposition to issuer · Disposed 23,439 · Balance 0 F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.
F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.
F3: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 23, 2026 Filed Sep 25, 2026 00:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 23,439 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 3 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: As of immediately prior to the Effective Time, each award of performance restricted stock units of the Issuer (a "Company PSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled in exchange for the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares with respect to such Company PSU Award that remained outstanding and unreleased as of immediately prior to the Effective Time, plus (iii) one CVR for each Ordinary Share underlying such Company PSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 108,436 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 2 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,439 F2 · price: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. Read SEC document |
| September 23, 2026 Filed Sep 25, 2026 00:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Disposition to issuerOrdinary Shares | 204,966 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001961289-26-000011 · form4-09252026_120949.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,875 F1 · price: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 22:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,112 | $16.95 | $137,498.40 |
DisclosureSEC source: 0001961289-26-000008 · form4-08242026_100819.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,841 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:25 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,670 | $16.55 | $143,488.50 |
DisclosureSEC source: 0001961289-26-000006 · form4-05222026_100506.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,953 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 22:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001961289-26-000004 · form4-04032026_100414.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 353,623 Read SEC document |
| February 20, 2026 Filed Feb 25, 2026 00:40 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 20,672 | $19.66 | $406,411.52 |
DisclosureSEC source: 0001961289-26-000002 · form4-02252026_120248.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,123 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 23:16 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 18,627 | $17.90 | $333,423.30 |
DisclosureSEC source: 0001961289-25-000006 · form4-11242025_111155.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,795 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2025 Filed Aug 22, 2025 22:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 9,368 | $13.39 | $125,437.52 |
DisclosureSEC source: 0001415889-25-022801 · form4-08222025_100803.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,422 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2025 Filed May 22, 2025 22:42 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 9,348 | $9.45 | $88,338.60 |
DisclosureSEC source: 0001415889-25-014261 · form4-05222025_100548.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 364,790 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 23:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-006679 · form4-03042025_110322.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 374,138 Read SEC document |
| February 20, 2025 Filed Feb 25, 2025 00:30 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 13,751 | $9.66 | $132,834.66 |
DisclosureSEC source: 0001415889-25-005353 · form4-02252025_120230.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,138 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 23:09 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,477 | $9.97 | $84,515.69 |
DisclosureSEC source: 0001415889-24-027571 · form4-11222024_111127.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,889 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2024 Filed Aug 23, 2024 00:07 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,635 | $8.22 | $70,979.70 |
DisclosureSEC source: 0001415889-24-022090 · form4-08232024_120846.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 321,366 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2024 Filed May 22, 2024 22:08 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,635 | $9.10 | $78,578.50 |
DisclosureSEC source: 0001415889-24-014139 · form4-05222024_100507.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 330,001 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| April 02, 2024 Filed Apr 4, 2024 22:15 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010326 · form4-04042024_100421.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 338,636 F1 · shares: On April 2, 2024, the reporting person was granted 100,000 RSUs. 37,500 RSUs are subject to service-based vesting conditions and the remaining 62,500 RSUs vest based on the achievement of share price appreciation targets as well as continued employment. Read SEC document |
| February 20, 2024 Filed Feb 23, 2024 01:11 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 17,036 | $8.92 | $151,961.12 |
DisclosureSEC source: 0001415889-24-004966 · form4-02232024_010249.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,636 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 23:14 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,187 | $10.37 | $64,159.19 |
DisclosureSEC source: 0001415889-23-015452 · form4-11222023_111102.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 255,672 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| August 20, 2023 Filed Aug 22, 2023 22:17 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 7,114 | $9.70 | $69,005.80 |
DisclosureSEC source: 0001415889-23-012520 · form4-08222023_100801.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,859 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| May 20, 2023 Filed May 23, 2023 23:46 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 8,744 | $11.21 | $98,020.24 |
DisclosureSEC source: 0001415889-23-008674 · form4-05232023_110519.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,973 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:38 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | GrantOrdinary Shares | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004275 · form4-03042023_010338.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,717 Read SEC document |
| February 20, 2023 Filed Feb 23, 2023 00:27 UTC | Theravance Biopharma, Inc. TBPH · Entity 5037 | Tax withholdingOrdinary Shares | 6,783 | $10.44 | $70,814.52 |
DisclosureSEC source: 0001415889-23-003075 · form4-02232023_120258.xml · nonDerivative · entry 1 Sawaf Aziz · CIK 0001961289 · SVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,717 F1 · shares: Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.